Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B

Details for Australian Patent Application No. 2010200271 (hide)

Owner Philogen S.p.A. Bayer Schering Pharma Aktiengesellschaft

Inventors Hilger, Christoph-Stephan; Borsi, Laura; Balza, Enrica; Castellani, Patrizia; Zardi, Luciano; Friebe, Matthias; Carnemolla, Barbara

Agent Davies Collison Cave

Pub. Number AU-A-2010200271

Parent 2004269897

Filing date 22 January 2010

Wipo publication date 18 February 2010

International Classifications

A61K 51/10 (2006.01) Preparations containing radioactive substances for use in therapy or testing

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

11 February 2010 Complete Application Filed

18 February 2010 Application Open to Public Inspection

  Published as AU-A-2010200271

29 March 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010200272-Multi-Purpose Storage System For Jerry Can Holders

2010200270-DNA mutagenesis by random fragmentation and reassembly